Pharma firm gets federal contract funds
Morphotek Inc. of Exton said today that it will receive $1.6 million in additional funding from the Department of Defense to continue developing treatments for infectious diseases.
Morphotek Inc. of Exton said today that it will receive $1.6 million in additional funding from the Department of Defense to continue developing treatments for infectious diseases.
The privately held company received $1.7 million in initial funding from the department in June. The project involves therapies aimed at staphylococcal-derived toxins. Morphotek said its technology neutralizes the toxic effects of pathogens caused by biowarfare.
Morphotek is working on the project with the U.S. Army Medical Research Institute of Infectious Diseases in Fort Detrick, Md.
The biopharmaceutical company specializes in the development of protein and antibody products.
























